Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Risk Factors of Jaw Osteoradionecrosis in Oral Cavity Cancer Patients Post-Radiotherapy (AOITC)

17. September 2026 aktualisiert von: AO Innovation Translation Center

Risk Factors of Jaw Osteoradionecrosis in Oral Cavity Cancer Patients Post-Radiotherapy: A Multi-center Retrospective Cohort Study

Osteoradionecrosis (ORN) of the jaw is a serious complication that can occur after radiation therapy for head and neck cancers, including oral cavity cancer (OCC). ORN happens when jawbone tissue dies and fails to heal, often triggered by dental issues like tooth extractions or poorly fitting dentures. Symptoms can include exposed bone, pain, difficulty opening the mouth, trouble swallowing, and even jaw fractures-leading to major physical and emotional challenges.

The likelihood of ORN varies widely, from less than 1% to over 50% in head and neck cancer patients. For OCC specifically, studies report rates from 4% up to 25%. Treatment depends on how much bone is affected and can range from medication to major surgery.

Risk factors include radiation dose, tumor location, oral health, dental extractions, lifestyle habits (like alcohol use), and other health conditions. Poor oral hygiene, high radiation doses, and alcohol use are among the most common risks. However, current data on OCC patients is limited and often not broadly applicable.

This study will retrospectively examine what increases the risk of ORN in OCC patients who received radiation therapy before or after surgery. Using data from multiple international centers, it aims to identify patterns and provide globally relevant insights. The results will help guide prevention strategies and create evidence-based guidelines to reduce ORN and improve long-term outcomes for these patients.

Studienübersicht

Status

Noch keine Rekrutierung

Bedingungen

Studientyp

Beobachtungs

Einschreibung (Geschätzt)

1000

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienkontakt

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

18 Jahre und älter (Erwachsene, Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Alle

Probenahmeverfahren

Nicht-Wahrscheinlichkeitsprobe

Studienpopulation

Patients will be selected from the primary care center where the patients received their initial treatment and followed up for at least 24months

Beschreibung

Inclusion Criteria:

  • Adults (≥18 years) diagnosed with OCC and treated with radiotherapy with curative intent (preoperative or/and postoperative, not palliative; definitive RT)
  • Patients who completed the full prescribed radiotherapy course; patients remain eligible if radiotherapy was discontinued due to suspected and subsequently confirmed ORN
  • Available, complete medical records including RT details, oral status, comorbidities, dental procedure details (as applicable), and lifestyle factors (as applicable)
  • Documented informed consent from the treated patient, where applicable, permitting the use of their medical records for research purposes, in accordance with the requirements of the Institutional Review Board (IRB) or Ethics Committee (EC).
  • Availability of at least 24 months of follow-up data after completion of radiotherapy, or follow-up until the occurrence of ORN, death, or loss to follow-up, whichever occurs first.
  • Completion of the radiotherapy course on or before 31 December 2024.

Exclusion Criteria:

  • Patients with non-oral cavity primary cancers (eg, oropharynx, larynx)
  • Patients treated only with surgery or conservatively, without any form of RT
  • Incomplete or missing medical records
  • Record of use of antiresorptive (eg, bisphosphonate, denosumab) and antiangiogenic drugs
  • Patients with jaw necrosis attributable to non-radiation-related causes, such as medication-related osteonecrosis of the jaw (MRONJ), trauma, or odontogenic infections
  • Patients with known metastatic bone disease in the jaw
  • Patients who discontinued radiotherapy for reasons unrelated to ORN suspicion or confirmation (eg, death, dropout, treatment intolerance, or other non-ORN related causes)

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Beobachtungsmodelle: COHORT
  • Zeitperspektiven: RETROSPECTIVE

Kohorten und Interventionen

Gruppe / Kohorte
Cases (ORN group)

Developed clinically and radiographically or histologically confirmed osteoradionecrosis (ORN) of the jaw following radiotherapy.

Control (non-ORN group)

No clinical, radiological, or histological diagnosis of ORN during the follow-up period.

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Development of osteoradionecrosis (ORN) of the jaw
Zeitfenster: After completion of pre-and/or postoperative radiotherapy up to 24 months

The primary outcome is the development occurrence (yes/no) of ORN after completion of pre- and/or postoperative RT. The objective is to identify and evaluate patient-, tumor-, treatment-, and region-related risk factors associated with the development of ORN across multiple geographic regions.

Scoring Scale:

The primary endpoint will be treated as a binary variable:

0 = No ORN

1 = Development of ORN Time to ORN onset (interval between completion of RT and clinical diagnosis of ORN) will also be recorded for time-to-event analyses.

After completion of pre-and/or postoperative radiotherapy up to 24 months

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Incidence of ORN Across Geographic Regions
Zeitfenster: After completion of pre-and/or postoperative radiotherapy up to 24 months

To compare the incidence rates across geographical regions, namely between the Eastern and Western world, and High-Income Countries versus Low and Middle-Income Countries.

After completion of pre-and/or postoperative radiotherapy up to 24 months
Severity of ORN by Tumor Characteristic
Zeitfenster: After completion of pre-and/or postoperative radiotherapy up to 24 months

To evaluate the variability in the severity of osteoradionecrosis (ORN) based on primary tumor site (eg, tongue, floor of mouth, oral tongue, buccal mucosa, gingiva), histological tumor type (eg, adenoid cystic carcinoma, squamous cell carcinoma), and tumor characteristics including size, clinical stage (T1-T4), overall stage (III-IVA), and nodal status (N0, N1-2B, N2C, N3

After completion of pre-and/or postoperative radiotherapy up to 24 months
Association between radiotherapy dose and ORN severity
Zeitfenster: After completion of pre-and/or postoperative radiotherapy up to 24 months

To investigate the association between radiotherapy dose parameters (total dose and duration) and the severity grade of ORN among patients who develop ORN. Is there a correlation between increased radiation dose and duration and the severity of the condition?

After completion of pre-and/or postoperative radiotherapy up to 24 months
Incidence and severity comparison of preop vs. postop RT
Zeitfenster: After completion of pre-and/or postoperative radiotherapy up to 24 months

To compare the incidence and severity of ORN in patients undergoing preoperative versus postoperative radiotherapy

After completion of pre-and/or postoperative radiotherapy up to 24 months
Incidence comparison across RT modalities
Zeitfenster: After completion of pre-and/or postoperative radiotherapy up to 24 months

To compare the incidence ORN across different radiation modalities, including intensity-modulated radiotherapy (IMRT), volumetric modulated arc therapy (VMAT), and conventional three-dimensional conformal radiotherapy (3D-CRT)

After completion of pre-and/or postoperative radiotherapy up to 24 months
To determine whether the mandible is more susceptible to ORN than the maxilla, or vice versa.
Zeitfenster: After completion of pre-and/or postoperative radiotherapy up to 24 months

To determine whether the mandible is more susceptible to ORN than the maxilla, or vice versa.

After completion of pre-and/or postoperative radiotherapy up to 24 months
Complication evaluation with pre- or postop RT
Zeitfenster: After completion of pre-and/or postoperative radiotherapy up to 24 months

To evaluate potential complications associated with preoperative and postoperative radiotherapy

After completion of pre-and/or postoperative radiotherapy up to 24 months
To analyze the influence of pre-radiotherapy dental extractions and oral hygiene status on the risk of developing ORN
Zeitfenster: After completion of pre-and/or postoperative radiotherapy up to 24 months

To analyze the influence of pre-radiotherapy dental extractions and oral hygiene status on the risk of developing ORN

After completion of pre-and/or postoperative radiotherapy up to 24 months
To examine the variability in ORN incidence and severity between patients who undergo dental extractions before versus after the completion of RT
Zeitfenster: After completion of pre-and/or postoperative radiotherapy up to 24 months

To examine the variability in ORN incidence and severity between patients who undergo dental extractions before versus after the completion of RT

After completion of pre-and/or postoperative radiotherapy up to 24 months

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Sponsor

Ermittler

  • Hauptermittler: Khalid Abdel-Galil, MD, Hamad Medical Corporation PO Box 3050 Doha, Qatar

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Geschätzt)

1. März 2027

Primärer Abschluss (Geschätzt)

15. Juni 2029

Studienabschluss (Geschätzt)

15. Juli 2029

Studienanmeldedaten

Zuerst eingereicht

27. Juli 2026

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

17. September 2026

Zuerst gepostet (Tatsächlich)

23. September 2026

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

23. September 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

17. September 2026

Zuletzt verifiziert

1. Juli 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Andere Studien-ID-Nummern

  • ORN of the Jaw

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

UNENTSCHIEDEN

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Nein

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .